therapeutic development

Transform Therapies, Reimagine Lives Our Mission Transform treatment for immune-mediated diseases, empower people to reimagine their lives. About Alumis Our Programs We are advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases. PIPELINE Our Approach Our precision approach builds on integrated scientific insights – powered by our proprietary data analytics platform – to drive smarter therapeutic development. science Our Culture We foster a culture where teams elevate, challenge, and nurture each other, living our values while driving our mission forward. careers News October 9, 2026 Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures September 4, 2026 Alumis to Participate in Upcoming.

clinical trialsdata analytics platformdrug discovery

Apricity Health is a precision oncology company founded by physicians and scientists. It aims to bring world-class expert care to patients everywhere using digital health technologies and smart analytics, capturing longitudinal ePRO, EHR and genomic data from diverse patient populations to enhance care, learn from patient data, and develop precision therapeutics.

digital health technologiesdrug discoverypatient data capturesmart analytics

Aqualung Therapeutics is a clinical stage immunotherapeutics company developing targeted therapies for inflammatory injury, fibrosis, and vascular leak. Its eNamptor platform includes ALT-100, a humanized monoclonal antibody designed to neutralize eNAMPT, along with complementary biomarker tools to support precision guided treatment.

biomarker developmentclinical developmenttranslational research

Blue Zone Therapeutics is a company developing innovative, effective, and practical treatments targeting age-related diseases in pets, aiming to create 'blue zones' for pets where longevity and vitality are the norm. It brings together scientists and veterinarians to advance pet healthcare through novel approaches and cutting-edge research, integrating science with compassionate care.

gene therapy researchneuroscience researchveterinary research

Caren Pharma develops hormone-based therapeutics for age-related diseases, reformulating clinically validated agents into novel treatments targeting the biological drivers of cognitive decline. Its lead program combines two FDA-approved drugs repurposed to address age-related memory loss, aiming to reach patients faster and more effectively.

drug reformulationdrug repurposing

Celmatix Inc. is a US-based women's health biotech company dedicated to translating advances in female biology into novel therapeutics. Its discovery portfolio spans infertility, endometriosis, and ovarian aging, including a first-in-class oral FSH receptor agonist, a JNK inhibitor for endometriosis, and AMH-targeting antibodies. Celmatix was selected to receive a $3.5 million award from ARPA-H's Sprint for Women's Health.

drug discovery

CIAN, Inc. is a Delaware-incorporated start-up company founded by Professor Ramchandran in March 2023 and based in Wisconsin. It develops biomarkers based on ciliary proteins found in blood to inform changes in blood flow associated with disease, aiming for point-of-care testing that diagnoses disease severity and prognosticates outcomes. The technology stems from research at the Medical College of Wisconsin on cilia loss from endothelial cells under turbulent flow (deciliation).

biomarker developmentdiagnostics developmentresearch on cilia in brain blood vessel development

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases. Its approach targets bacterial biofilms, the driver of many progressive lung diseases, aiming to modify the course of chronic respiratory disease rather than just manage symptoms. Its investigational agent is CMTX-101, evaluated in a Phase 2a study in cystic fibrosis.

clinical developmentclinical trials

Connetics Consulting brings together people, policy, and science to develop, implement, and evaluate solutions for rare diseases and newborn screening. With decades of experience in the public health genetics, genomics, and rare disease space, the firm works with organizations on initiatives aimed at increasing knowledge, research, and access for rare disease patients and their families through scientific and technical consulting and policy and advocacy support.

content creation and disseminationoperations and implementationpolicy and advocacystrategytechnical expertise and assistancetechnology and analytics

Cortexa Therapeutics is a neuroscience company developing therapies that target biological mechanisms shared across neurodegenerative diseases to restore neuronal homeostasis. Its first program, CRTX-101, targets calcium-permeable AMPA receptors (CP-AMPARs) as mediators of excitotoxic calcium overload in ALS. The company was founded by Nathan Cole following his ALS diagnosis at age 31 and is advised by a scientific board spanning motor neuron biology, ALS neurobiology and excitotoxicity, and translational neurodegeneration research.

drug discoveryneuroscience research

Corvidane is a privately held life sciences company developing novel therapeutic approaches for cardiometabolic disease, including atherosclerosis and metabolic dysfunction associated steatohepatitis (MASH). Its lead programme, CVMB-216, is a patented orally administered, multi-pathway therapeutic that activates a spectrum of clinically validated targets spanning lipid metabolism, inflammation and fibrosis. The company advances programmes through structured preclinical development toward regulated clinical pathways and pursues two indications for FDA app

clinical developmentdrug developmentpreclinical developmentprocess scale-uptranslational research

ENCUE is a Northwestern spinout developing novel modulators and therapeutics for neurodegenerative and psychiatric disorders. Its approach targets synaptic function and neuroplasticity to restore synaptic health and normal cognition, with a focus on the IGF2R receptor. The company reports six molecules currently in Phase 2/3 clinical trials.

clinical research and developmentdrug discoverymedicinal chemistry

Endios Bio develops novel therapeutics for ALS and rare neurological diseases based on breakthrough discoveries from Harvard Medical School and the University of Colorado Boulder. Founded through CU Boulder's Embark Deep Tech Startup Creator, the company targets PEG10, a newly discovered driver of ALS and neurodevelopmental disorders, with two patented therapeutic programs aimed at neutralizing PEG10.

drug discoverymolecular biology research

Envisagenics is a biotechnology company that uses its AI platform, SpliceCore®, to power the discovery and therapeutic targeting of RNA splicing. Combining expertise in RNA biology and AI, the company discovers novel, disease-specific drug targets in immuno-oncology and RNA-targeted treatments for neurodegenerative diseases. Founded in 2014, it is based in Long Island City, New York.

AI-driven analysis of RNA splicingdrug target discoveryRNA biology

Epicrispr Biotechnologies is a biotechnology company developing therapies to dynamically control gene expression and treat complex disease. It leverages the epigenome and its Gene Expression Modulation System (GEMS) platform, an epigenomic modulator toolbox that can be combined to create therapies customized for specific disease indications. The company is located in South San Francisco, CA.

epigenomic modulationgene expression modulation

Flavocure Biotech, Inc. is a biotechnology company focused on discovering and developing next-generation cures for patients, aiming to transform natural products into new cures. It is developing a Theranostic platform called NanoCaflanone™ targeting neurological diseases such as Alzheimer's and Parkinson's disease, as well as aggressive and rare cancers including pancreatic cancer and brain cancer.

drug delivery across blood-brain barrierdrug discoveryMRI imagingnanoparticle-based theranostic platform